Ray Therapeutics has reached a pivotal regulatory milestone as its lead candidate, RTx-015, was granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA). This follows the therapy’s recent RMAT designation from the US FDA, further validating its potential to treat severe retinal degeneration.
1. Breakthrough Optogenetic Approach
RTx-015 is an optogenetic gene therapy targeting Retinitis Pigmentosa (RP), a leading cause of progressive blindness.
-
Mechanism of Action: The therapy utilizes a bioengineered, light-sensitive protein to turn remaining retinal cells into functional photoreceptors.
-
Genotype-Independent Innovation: Unlike traditional gene therapies that target specific mutations, RTx-015 aims to restore vision regardless of the underlying genetic cause, delivered via a single intravitreal injection.
2. Promising Clinical Outcomes
The EMA’s PRIME status was supported by encouraging preliminary safety and efficacy data from an ongoing Phase I/II clinical trial.
-
Visual Improvement: Patients across all dosage levels reported meaningful enhancements in visual function in the treated eye.
-
Clinical Validation: These outcomes underscore the therapy’s potential to address the significant unmet medical needs of patients with advanced stages of RP.
3. Pipeline Expansion in Retinal Health
Ray Therapeutics continues to diversify its gene therapy portfolio with its second program, RTx-021.
-
Target Indications: This program focuses on macular diseases, including Stargardt disease and geographic atrophy age-related macular degeneration.
-
Strategic Backing: Supported by the California Institute for Regenerative Medicine, RTx-021 reinforces the company’s commitment to tackling a broad spectrum of blinding conditions.
Paul Bresge, Co-founder and CEO of Ray Therapeutics, stated that these dual designations from the FDA and EMA will accelerate the global development of RTx-015, bringing the company closer to its mission of restoring vision for patients worldwide.
Source: https://www.pharmaceutical-technology.com/news/ray-therapeutics-ema-prime-status/?cf-view